<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37196635</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2666-3791</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>Cell reports. Medicine</Title><ISOAbbreviation>Cell Rep Med</ISOAbbreviation></Journal><ArticleTitle>Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy.</ArticleTitle><Pagination><StartPage>101036</StartPage><MedlinePgn>101036</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101036</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xcrm.2023.101036</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-3791(23)00150-7</ELocationID><Abstract><AbstractText>Genetic and in&#xa0;vivo evidence suggests that aberrant recognition of RNA-containing autoantigens by Toll-like receptors (TLRs) 7 and 8 drives autoimmune diseases. Here we report on the preclinical characterization of MHV370, a selective oral TLR7/8 inhibitor. In&#xa0;vitro, MHV370 inhibits TLR7/8-dependent production of cytokines in human and mouse cells, notably interferon-&#x3b1;, a clinically validated driver of autoimmune diseases. Moreover, MHV370 abrogates B cell, plasmacytoid dendritic cell, monocyte, and neutrophil responses downstream of TLR7/8. In&#xa0;vivo, prophylactic or therapeutic administration of MHV370 blocks secretion of TLR7 responses, including cytokine secretion, B cell activation, and gene expression of, e.g., interferon-stimulated genes. In the NZB/W F1 mouse model of lupus, MHV370 halts disease. Unlike hydroxychloroquine, MHV370 potently blocks interferon responses triggered by specific immune complexes from systemic lupus erythematosus patient sera, suggesting differentiation from clinical standard of care. These data support advancement of MHV370 to an ongoing phase 2 clinical trial.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hawtin</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andr&#xe9;</LastName><ForeName>C&#xe9;dric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collignon-Zipfel</LastName><ForeName>G&#xe9;raldine</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appenzeller</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, Rheumatology, and Traumatology, School of Medical Science, University of Campinas (UNICAMP), Campinas, 13083-887 S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bannert</LastName><ForeName>Bettina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, University Hospital Basel and University of Basel, 4031 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumgartner</LastName><ForeName>Lea</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck</LastName><ForeName>Damian</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betschart</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulay</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunner</LastName><ForeName>Hermine I</ForeName><Initials>HI</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceci</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deane</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, La Jolla, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feifel</LastName><ForeName>Roland</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrero</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kyburz</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, University Hospital Basel and University of Basel, 4031 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lafossas</LastName><ForeName>Frederique</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loetscher</LastName><ForeName>Pius</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merz-Stoeckle</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michellys</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, La Jolla, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuesslein-Hildesheim</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raulf</LastName><ForeName>Friedrich</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rush</LastName><ForeName>James S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruzzante</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaharevitz</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, La Jolla, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wieczorek</LastName><ForeName>Grazyna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siegel</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gergely</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shisha</LastName><ForeName>Tamas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Junt</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland. Electronic address: tobias.junt@novartis.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep Med</MedlineTA><NlmUniqueID>101766894</NlmUniqueID><ISSNLinking>2666-3791</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051199">Toll-Like Receptor 7</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051199" MajorTopicYN="N">Toll-Like Receptor 7</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Toll-like receptors</Keyword><Keyword MajorTopicYN="N">antagonist</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">lupus</Keyword><Keyword MajorTopicYN="N">pharmacology</Keyword></KeywordList><CoiStatement>Declaration of interests All authors except S.A., B.B., H.I.B., J.D., D.K., P.M., F.R., and J.S.R. are current employees and shareholders of Novartis Pharma AG. MHV370 is described in patent WO2018047081.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>18</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37196635</ArticleId><ArticleId IdType="pmc">PMC10213863</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2023.101036</ArticleId><ArticleId IdType="pii">S2666-3791(23)00150-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Junt T., Barchet W. Translating nucleic acid-sensing pathways into therapies. Nat. Rev. Immunol. 2015;15:529&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">26292638</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.H., Choi S.J., Ji J.D., Song G.G. Association between toll-like receptor polymorphisms and systemic lupus erythematosus: a meta-analysis update. Lupus. 2016;25:593&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">26762473</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Ortiz H., Vel&#xe1;zquez-Cruz R., Espinosa-Rosales F., Jim&#xe9;nez-Morales S., Baca V., Orozco L. Association of TLR7 copy number variation with susceptibility to childhood-onset systemic lupus erythematosus in Mexican population. Ann. Rheum. Dis. 2010;69:1861&#x2013;1865.</Citation><ArticleIdList><ArticleId IdType="pubmed">20525845</ArticleId></ArticleIdList></Reference><Reference><Citation>Souyris M., Cenac C., Azar P., Daviaud D., Canivet A., Grunenwald S., Pienkowski C., Chaumeil J., Mej&#xed;a J.E., Gu&#xe9;ry J.C. TLR7 escapes X chromosome inactivation in immune cells. Sci. Immunol. 2018;3:eaap8855.</Citation><ArticleIdList><ArticleId IdType="pubmed">29374079</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyn-Cook B.D., Xie C., Oates J., Treadwell E., Word B., Hammons G., Wiley K. Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: ethnic differences and potential new targets for therapeutic drugs. Mol. Immunol. 2014;61:38&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">24865418</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsuda A., Wakui H., Iwamoto K., Ozawa M., Togashi M., Masai R., Maki N., Hatakeyama T., Sawada K. Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin. Exp. Immunol. 2008;152:482&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2453201</ArticleId><ArticleId IdType="pubmed">18373699</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown G.J., Ca&#xf1;ete P.F., Wang H., Medhavy A., Bones J., Roco J.A., He Y., Qin Y., Cappello J., Ellyard J.I., et al. TLR7 gain-of-function genetic variation causes human lupus. Nature. 2022;605:349&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9095492</ArticleId><ArticleId IdType="pubmed">35477763</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006;25:417&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">16973389</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairhurst A.M., Hwang S.H., Wang A., Tian X.H., Boudreaux C., Zhou X.J., Casco J., Li Q.Z., Connolly J.E., Wakeland E.K. Yaa autoimmune phenotypes are conferred by overexpression of TLR7. Eur. J. Immunol. 2008;38:1971&#x2013;1978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2993003</ArticleId><ArticleId IdType="pubmed">18521959</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarese E., Steinberg C., Pawar R.D., Reindl W., Akira S., Anders H.J., Krug A. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum. 2008;58:1107&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pubmed">18383384</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee P.Y., Kumagai Y., Li Y., Takeuchi O., Yoshida H., Weinstein J., Kellner E.S., Nacionales D., Barker T., Kelly-Scumpia K., et al. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J.&#xa0;Exp. Med. 2008;205:2995&#x2013;3006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605237</ArticleId><ArticleId IdType="pubmed">19047436</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane J.A., Pisitkun P., Barrett R.S., Feigenbaum L., Town T., Ward J.M., Flavell R.A., Bolland S. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity. 2007;27:801&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706502</ArticleId><ArticleId IdType="pubmed">17997333</ArticleId></ArticleIdList></Reference><Reference><Citation>Guiducci C., Gong M., Cepika A.M., Xu Z., Tripodo C., Bennett L., Crain C., Quartier P., Cush J.J., Pascual V., et al. RNA recognition by human TLR8 can lead to autoimmune inflammation. J.&#xa0;Exp. Med. 2013;210:2903&#x2013;2919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3865472</ArticleId><ArticleId IdType="pubmed">24277153</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrat F.J., Meeker T., Gregorio J., Chan J.H., Uematsu S., Akira S., Chang B., Duramad O., Coffman R.L. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J.&#xa0;Exp. Med. 2005;202:1131&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213213</ArticleId><ArticleId IdType="pubmed">16230478</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawar R.D., Ramanjaneyulu A., Kulkarni O.P., Lech M., Segerer S., Anders H.J. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J.&#xa0;Am. Soc. Nephrol. 2007;18:1721&#x2013;1731.</Citation><ArticleIdList><ArticleId IdType="pubmed">17460144</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlach J., Bender A.T., Przetak M., Pereira A., Deshpande A., Johnson T.L., Reissig S., Tzvetkov E., Musil D., Morse N.T., et al. Discovery of M5049: a novel selective toll-like receptor 7/8 inhibitor for treatment of autoimmunity. J.&#xa0;Pharmacol. Exp. Therapeut. 2021;376:397&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">33328334</ArticleId></ArticleIdList></Reference><Reference><Citation>Balak D.M.W., van Doorn M.B.A., Arbeit R.D., Rijneveld R., Klaassen E., Sullivan T., Brevard J., Thio H.B., Prens E.P., Burggraaf J., Rissmann R. IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. Clin. Immunol. 2017;174:63&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">27876460</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilstra J.S., John S., Gordon R.A., Leibler C., Kashgarian M., Bastacky S., Nickerson K.M., Shlomchik M.J. B cell-intrinsic TLR9 expression is protective in murine lupus. J.&#xa0;Clin. Invest. 2020;130:3172&#x2013;3187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260024</ArticleId><ArticleId IdType="pubmed">32191633</ArticleId></ArticleIdList></Reference><Reference><Citation>Alper P.B., Deane J., Betschart C., Buffet D., Collignon Zipfel G., Gordon P., Hampton J., Hawtin S., Ibanez M., Jiang T., et al. Discovery of potent, orally bioavailable in&#xa0;vivo efficacious antagonists of the TLR7/8 pathway. Bioorg. Med. Chem. Lett. 2020;30:127366.</Citation><ArticleIdList><ArticleId IdType="pubmed">32738975</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopal D., Paturel C., Morel Y., Uematsu S., Akira S., Diebold S.S. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood. 2010;115:1949&#x2013;1957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837337</ArticleId><ArticleId IdType="pubmed">20065291</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsbach A., Nemorin J.G., Montino C., M&#xfc;ller C., Samulowitz U., Vicari A.P., Jurk M., Mutwiri G.K., Krieg A.M., Lipford G.B., Vollmer J. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. JImmunol. 2008;180:3729&#x2013;3738.</Citation><ArticleIdList><ArticleId IdType="pubmed">18322178</ArticleId></ArticleIdList></Reference><Reference><Citation>Gestermann N., Di Domizio J., Lande R., Demaria O., Frasca L., Feldmeyer L., Di Lucca J., Gilliet M. Netting neutrophils activate autoreactive B cells in lupus. J.&#xa0;Immunol. 2018;200:3364&#x2013;3371.</Citation><ArticleIdList><ArticleId IdType="pubmed">29632142</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann M., Arruda-Silva F., Bianchetto-Aguilera F., Finotti G., Calzetti F., Scapini P., Lunardi C., Cassatella M.A., Tamassia N. IFNalpha enhances the production of IL-6 by human neutrophils activated via TLR8. Sci. Rep. 2016;6:19674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4726390</ArticleId><ArticleId IdType="pubmed">26790609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H., Dietsch G.N., Matthews M.A.H., Yang Y., Ghanekar S., Inokuma M., Suni M., Maino V.C., Henderson K.E., Howbert J.J., et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin. Cancer Res. 2012;18:499&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">22128302</ArticleId></ArticleIdList></Reference><Reference><Citation>Baenziger S., Heikenwalder M., Johansen P., Schlaepfer E., Hofer U., Miller R.C., Diemand S., Honda K., Kundig T.M., Aguzzi A., Speck R.F. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood. 2009;113:377&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">18824599</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau R., Hong S., Cantarel B., Baldwin N., Baisch J., Edens M., Cepika A.M., Acs P., Turner J., Anguiano E., et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016;165:1548&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">27259156</ArticleId></ArticleIdList></Reference><Reference><Citation>Omdal R., Brokstad K., Waterloo K., Koldingsnes W., Jonsson R., Mellgren S.I. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur. J. Neurol. 2005;12:392&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">15804272</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowal C., Degiorgio L.A., Lee J.Y., Edgar M.A., Huerta P.T., Volpe B.T., Diamond B. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl. Acad. Sci. USA. 2006;103:19854&#x2013;19859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1702320</ArticleId><ArticleId IdType="pubmed">17170137</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo-Zehnder M., Toledo E.M., Segovia-Miranda F., Serrano F.G., Benito M.J., Metz C., Retamal C., &#xc1;lvarez A., Massardo L., Inestrosa N.C., Gonz&#xe1;lez A. Anti-ribosomal P protein autoantibodies from patients with neuropsychiatric lupus impair memory in mice. Arthritis Rheumatol. 2015;67:204&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">25302407</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami Y., Fukui R., Tanaka R., Motoi Y., Kanno A., Sato R., Yamaguchi K., Amano H., Furukawa Y., Suzuki H., et al. Anti-TLR7 antibody protects against lupus nephritis in NZBWF1 mice by targeting B cells and patrolling monocytes. Front. Immunol. 2021;12:777197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8632649</ArticleId><ArticleId IdType="pubmed">34868046</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;vgren T., Eloranta M.L., B&#xe5;ve U., Alm G.V., R&#xf6;nnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004;50:1861&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">15188363</ArticleId></ArticleIdList></Reference><Reference><Citation>Eloranta M.L., L&#xf6;vgren T., Finke D., Mathsson L., R&#xf6;nnelid J., Kastner B., Alm G.V., R&#xf6;nnblom L. Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 2009;60:2418&#x2013;2427.</Citation><ArticleIdList><ArticleId IdType="pubmed">19644885</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall'era M.C., Cardarelli P.M., Preston B.T., Witte A., Davis J.C., Jr. Type I interferon correlates with serological and clinical manifestations of SLE. Ann. Rheum. Dis. 2005;64:1692&#x2013;1697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1755300</ArticleId><ArticleId IdType="pubmed">15843451</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaul A., Gordon C., Crow M.K., Touma Z., Urowitz M.B., van Vollenhoven R., Ruiz-Irastorza G., Hughes G. Systemic lupus erythematosus. Nat. Rev. Dis. Prim. 2016;2:16039.</Citation><ArticleIdList><ArticleId IdType="pubmed">27306639</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuznik A., Bencina M., Svajger U., Jeras M., Rozman B., Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J.&#xa0;Immunol. 2011;186:4794&#x2013;4804.</Citation><ArticleIdList><ArticleId IdType="pubmed">21398612</ArticleId></ArticleIdList></Reference><Reference><Citation>Durcan L., Clarke W.A., Magder L.S., Petri M. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J.&#xa0;Rheumatol. 2015;42:2092&#x2013;2097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4630115</ArticleId><ArticleId IdType="pubmed">26428205</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirou K.A., Lee C., George S., Louca K., Peterson M.G.E., Crow M.K. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52:1491&#x2013;1503.</Citation><ArticleIdList><ArticleId IdType="pubmed">15880830</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodero M.P., Decalf J., Bondet V., Hunt D., Rice G.I., Werneke S., McGlasson S.L., Alyanakian M.A., Bader-Meunier B., Barnerias C., et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J.&#xa0;Exp. Med. 2017;214:1547&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5413335</ArticleId><ArticleId IdType="pubmed">28420733</ArticleId></ArticleIdList></Reference><Reference><Citation>Migita K., Miyashita T., Maeda Y., Kimura H., Nakamura M., Yatsuhashi H., Ishibashi H., Eguchi K. Reduced blood BDCA-2+ (lymphoid) and CD11c+ (myeloid) dendritic cells in systemic lupus erythematosus. Clin. Exp. Immunol. 2005;142:84&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1809479</ArticleId><ArticleId IdType="pubmed">16178860</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelis K.A., Norgard M.A., Levasseur P.R., Olson B., Burfeind K.G., Buenafe A.C., Zhu X., Jeng S., McWeeney S.K., Marks D.L. Persistent Toll-like receptor 7 stimulation induces behavioral and molecular innate immune tolerance. Brain Behav. Immun. 2019;82:338&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6956569</ArticleId><ArticleId IdType="pubmed">31499172</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., Shark K.B., Grande W.J., Hughes K.M., Kapur V., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA. 2003;100:2610&#x2013;2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151388</ArticleId><ArticleId IdType="pubmed">12604793</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra S.V., Guzm&#xe1;n R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., Li E.K.M., Thomas M., Kim H.Y., Le&#xf3;n M.G., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand E.F., Furie R., Tanaka Y., Bruce I.N., Askanase A.D., Richez C., Bae S.C., Brohawn P.Z., Pineda L., Berglind A., et al. Trial of anifrolumab in active systemic lupus erythematosus. N.&#xa0;Engl. J. Med. 2020;382:211&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Tummala R., Abreu G., Pineda L., Michaels M.A., Kalyani R.N., Furie R.A., Morand E.F. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci. Med. 2021;8:e000464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7893670</ArticleId><ArticleId IdType="pubmed">33597205</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang F., Glans H., Enoksson S.L., Kolios A.G.A., Lor&#xe9; K., Nilsson J. Recurrent herpes zoster ophthalmicus in a patient with a novel toll-like receptor 3 variant linked to compromised activation capacity in fibroblasts. J.&#xa0;Infect. Dis. 2020;221:1295&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pubmed">31268141</ArticleId></ArticleIdList></Reference><Reference><Citation>Sironi M., Peri A.M., Cagliani R., Forni D., Riva S., Biasin M., Clerici M., Gori A. TLR3 mutations in adult patients with herpes simplex virus and varicella-zoster virus encephalitis. J.&#xa0;Infect. Dis. 2017;215:1430&#x2013;1434.</Citation><ArticleIdList><ArticleId IdType="pubmed">28368532</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S.Y., Jouanguy E., Ugolini S., Smahi A., Elain G., Romero P., Segal D., Sancho-Shimizu V., Lorenzo L., Puel A., et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science. 2007;317:1522&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pubmed">17872438</ArticleId></ArticleIdList></Reference><Reference><Citation>Port A., Shaw J.V., Klopp-Schulze L., Bytyqi A., Vetter C., Hussey E., Mammasse N., Ona V., Bachmann A., Strugala D., et al. Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8. Pharmacol. Res. Perspect. 2021;9:e00842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8377444</ArticleId><ArticleId IdType="pubmed">34414672</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds J.A., Briggs T.A., Rice G.I., Darmalinggam S., Bondet V., Bruce E., Khan M., Haque S., Chinoy H., Herrick A.L., et al. Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles. Arthritis Res. Ther. 2019;21:147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6567906</ArticleId><ArticleId IdType="pubmed">31200750</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau C.M., Broughton C., Tabor A.S., Akira S., Flavell R.A., Mamula M.J., Christensen S.R., Shlomchik M.J., Viglianti G.A., Rifkin I.R., Marshak-Rothstein A. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J.&#xa0;Exp. Med. 2005;202:1171&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213226</ArticleId><ArticleId IdType="pubmed">16260486</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn S.S., Jung S.M., Yoo J., Lee S.W., Song J.J., Park Y.B. Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus. Rheumatol. Int. 2019;39:1937&#x2013;1944.</Citation><ArticleIdList><ArticleId IdType="pubmed">31552434</ArticleId></ArticleIdList></Reference><Reference><Citation>Arroyo-&#xc1;vila M., Santiago-Casas Y., McGwin G., Jr., Cantor R.S., Petri M., Ramsey-Goldman R., Reveille J.D., Kimberly R.P., Alarc&#xf3;n G.S., Vil&#xe1; L.M., Brown E.E. Clinical associations of anti-Smith antibodies in PROFILE: a multi-ethnic lupus cohort. Clin. Rheumatol. 2015;34:1217&#x2013;1223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4475431</ArticleId><ArticleId IdType="pubmed">25896533</ArticleId></ArticleIdList></Reference><Reference><Citation>Guiducci C., Gong M., Xu Z., Gill M., Chaussabel D., Meeker T., Chan J.H., Wright T., Punaro M., Bolland S., et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature. 2010;465:937&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964153</ArticleId><ArticleId IdType="pubmed">20559388</ArticleId></ArticleIdList></Reference><Reference><Citation>Umiker B.R., Andersson S., Fernandez L., Korgaokar P., Larbi A., Pilichowska M., Weinkauf C.C., Wortis H.H., Kearney J.F., Imanishi-Kari T. Dosage of X-linked Toll-like receptor 8 determines gender differences in the development of systemic lupus erythematosus. Eur. J. Immunol. 2014;44:1503&#x2013;1516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4028042</ArticleId><ArticleId IdType="pubmed">24500834</ArticleId></ArticleIdList></Reference><Reference><Citation>Demaria O., Pagni P.P., Traub S., de Gassart A., Branzk N., Murphy A.J., Valenzuela D.M., Yancopoulos G.D., Flavell R.A., Alexopoulou L. TLR8 deficiency leads to autoimmunity in mice. J.&#xa0;Clin. Invest. 2010;120:3651&#x2013;3662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947223</ArticleId><ArticleId IdType="pubmed">20811154</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona-Rivera C., Kaplan M.J. Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity. Semin. Immunopathol. 2013;35:455&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4007274</ArticleId><ArticleId IdType="pubmed">23553215</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J.&#xa0;Exp. Med. 2003;197:711&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193846</ArticleId><ArticleId IdType="pubmed">12642603</ArticleId></ArticleIdList></Reference><Reference><Citation>Aluri J., Bach A., Kaviany S., Chiquetto Paracatu L., Kitcharoensakkul M., Walkiewicz M.A., Putnam C.D., Shinawi M., Saucier N., Rizzi E.M., et al. Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function. Blood. 2021;137:2450&#x2013;2462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8109013</ArticleId><ArticleId IdType="pubmed">33512449</ArticleId></ArticleIdList></Reference><Reference><Citation>Brohawn P.Z., Streicher K., Higgs B.W., Morehouse C., Liu H., Illei G., Ranade K. Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures. Lupus. 2019;28:1524&#x2013;1533.</Citation><ArticleIdList><ArticleId IdType="pubmed">31660791</ArticleId></ArticleIdList></Reference><Reference><Citation>Ah Kioon M.D., Tripodo C., Fernandez D., Kirou K.A., Spiera R.F., Crow M.K., Gordon J.K., Barrat F.J. Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Sci. Transl. Med. 2018;10:eaam8458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9865429</ArticleId><ArticleId IdType="pubmed">29321259</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson M.D., McCarthy D.J., Smyth G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie M.E., Phipson B., Wu D., Hu Y., Law C.W., Shi W., Smyth G.K. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Korotkevich GS V., Budin N., Shpak B., Artyomov M.N., Sergushichev A. Fast gene set enrichment analysis. bioRxiv. 2016 doi: 10.1101/060012v32021. Preprint at.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/060012v32021</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberzon A., Subramanian A., Pinchback R., Thorvaldsd&#xf3;ttir H., Tamayo P., Mesirov J.P. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27:1739&#x2013;1740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3106198</ArticleId><ArticleId IdType="pubmed">21546393</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoepfel T., Nimsgern P., Jacquier S., Bourrel M., Vangrevelinghe E., Glatthar R., Behnke D., Alper P.B., Michellys P.Y., Deane J., et al. Target-based identification and optimization of 5-Indazol-5-yl pyridones as toll-like receptor 7 and 8 antagonists using a biochemical TLR8 antagonist competition assay. J.&#xa0;Med. Chem. 2020;63:8276&#x2013;8295.</Citation><ArticleIdList><ArticleId IdType="pubmed">32786235</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>